ERIS Lifesciences share price today

ERIS Lifesciences Ltd's share price was ₹1,215.00 at the close on 4 November 2026. It has been falling for 40 weeks. That is 10.1% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,096 and ₹1,666, and at that close it sat 21% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today ERIS Lifesciences Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 16 weeks running.

Over the last 9.3 years the share price moved +102% while the NIFTY 500 moved +159%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 17 July 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: revenue up on a year earlier for 12 quarters in a row (every quarter we can compare), foreign funds (FIIs) cut their stake for 6 quarters in a row and profit up on a year earlier for 7 quarters in a row.

1. Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare)

   In the September 2026 quarter revenue was ₹892 crore, +12.6% on a year earlier.

2. Foreign funds (FIIs) cut their stake for 6 quarters in a row

   From 8.4% to 5.7% of the company by the September 2026 quarter.

3. Profit up on a year earlier for 7 quarters in a row

   In the September 2026 quarter profit was ₹187 crore, +39.6% on a year earlier.

For July to September 2026 (the quarter ended 30 September 2026), ERIS Lifesciences reported revenue of ₹892 crore, up 12.6% from ₹792 crore a year earlier, and a profit of ₹187 crore, up 39.6% from ₹134 crore.

ERIS Lifesciences results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

ERIS Lifesciences' management discussed these results on a call held on 26 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

ERIS Lifesciences closed at ₹1,215.00 on 4 November 2026, down 23.8% from ₹1,594.20 a year earlier (7 November 2025) and up 49.0% over five years. Its highest weekly close since June 2017 was ₹1,808.40 on 1 August 2025.

ERIS Lifesciences share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

492 weekly closes from 30 June 2017 to 4 November 2026.

4 Nov 2026: ERIS Lifesciences closed at ₹1,215.00, up 5.1% on the week and up 2.1% on the month. 26 Oct 2026: ERIS Lifesciences held its results call for July to September 2026. Management guided: H2 operating margin around 35% now at 36% with further gross and operating profit gains ahead.

Earlier

• Results for July to September 2026: Revenue up 12.6% and profit up 39.6% on a year earlier.
• 29 May 2026: ex-date for an interim dividend of ₹7.21 a share.

ERIS Lifesciences paid ₹7.21 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.59% at the ₹1,215.00 close on 4 November 2026. The last was an interim dividend of ₹7.21 a share, ex-date 29 May 2026.

ERIS Lifesciences dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. ERIS Lifesciences Ltd paid out 16% of its profit as dividends in FY26, and it paid a dividend in 7 of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 26 October 2026, ERIS Lifesciences' management guided: H2 operating margin around 35% now at 36% with further gross and operating profit gains ahead.

“The market is ramping up well, and I feel that the market might double next year from where we started. It looks like we are now talking about 40-45 crores a month. I think next year we should be doing around 80-90 crores a month.”Amit Bakshi, on the call for July to September 2026

What management guided

• 100 basis points each from Bhopal and Zorvia over next two quarters to 150-200 basis points at full Bhopal Q2 next year shift, ramp from Q1.
• December quarter Swiss sales within 5% of last year at 25% margin; November shutdown with re-invite by year end; PV batches March-April, turnaround after Q1.
• Net debt paydown ₹150-200 crore this year and ₹400-500 crore next year; H2 capital spending ₹100 crore then sharp reduction.
• Effective tax rate 20-21% this year and next; Bhopal 15% levy versus 37% on outsourcing; added depreciation ₹30 crore on ₹200-300 crore capitalisation.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 26 October 2026.

When ERIS Lifesciences reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Bhopal volume shift from negligible base with flagged gross uplift and operating profit flow-through visible in print.

ERIS Lifesciences is on 2 of our India lists: Small & mid cap stocks and Pharma stocks.

ERIS Lifesciences Ltd earned ₹187 Cr of net profit in the Sep 2026 quarter, +39.6% on the same quarter a year earlier. That is the 7th quarter in a row of profit growth. Full-year FY26 profit was ₹648 Cr. Over 10 years profit has grown 17.0% a year on average. That is 21.0% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹134 Cr.

For the full year, FY26 profit was ₹648 Cr (+72.8% on the year before).

Why profit moved: revenue changed +12.6% on a year earlier and the margin moved −1.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +63.2% and revenue +11.0%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

ERIS Lifesciences Ltd reported ₹892 Cr of revenue in the Sep 2026 quarter, +12.6% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 18.0% a year on average. The last full year, FY26, came in at ₹3,129 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹3,329 Cr.

FY26 revenue was ₹3,129 Cr, +8.1% on the year before.

Recent pace: the last four quarters grew +11.0% on average, against 18.0% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +11.1%, against +15.4% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +60.3%, against +39.9% a year (accelerating).

ERIS Lifesciences Ltd's operating margin was 35.0% in the Sep 2026 quarter, 1.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 19.0% and 38.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −1.8 percentage points on the year while gross margin changed +0.2 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 147% of ERIS Lifesciences Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹538 Cr of operating cash against ₹648 Cr of profit. After ₹266 Cr of spending on assets, ₹272 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 147% of profit came in as cash: the cash cycle got 99 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 4.6× depreciation over three years. The next section checks what that spending is building.

ERIS Lifesciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 129 days in FY26, up from 30 days in FY21. It spent ₹3,547 Cr on assets over the last 3 years. Customers take 79 days to pay, and stock sits for 200 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹3,129 Cr, each day of that cycle ties up about ₹8.6 Cr, so roughly ₹1,106 Cr is tied up in the business at any time.

FY26: customers took 79 days to pay and stock sat for 200 days, about 6.6 months of sales sitting as stock, for a full cycle of 129 days, longer than FY21's 30.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 200 days. Customers pay about 79 days after that. Suppliers are paid at 151 days. Together that makes the 129-day cycle.

Spending on assets: ₹3,547 Cr over the last 3 years, against ₹778 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹171 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

ERIS Lifesciences Ltd's P/E is 22.6×, near the low end of its own history: it has been lower only 19% of the time. Its usual P/E (the middle reading) is 29.5×, over 9.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹51.18.

Why the multiple is where it is: over the past year earnings per share moved +73.1% while the price moved −23.8%. Earnings did better than the price, which pulled the multiple down within its own range.

Where the price move came from: over 5 years the price moved +8.3% a year; about +13.8% a year came from earnings growth and about −5.5 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

The PEG ratio and its quarterly curve, which only the second data source has, are not shown on this page: its two data sources disagree by up to 11% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

ERIS Lifesciences Ltd's business is getting better. EPS growth hit its low 6 quarters ago at −10.2% and has recovered to +67.7%, with ROCE steady at 14.0%. This is based on 9 quarters of 4 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.